tbuckley/cabot-search huggingface dataset:
Improvement Diagnosis and Treatment of Mantle Cell Lymphoma in a Middle-Income Country: A Time-Dependent Analysis in Mexico
Authors: Juan Rangel-Patiño, Perla R. R. Colunga-Pedraza, Gladys P Agreda, Oyuky Gissell Aguirre-Reyes, David Gomez-Almaguer, Ana Florencia Ramirez-Ibarguen
Journal: Blood (2021)
Abstract 8920: Type 2 Diabetes, Chronic Kidney Disease and Major Cardiovascular Events in Patients with Established Coronary Artery Disease
Authors: Lukas Sprenger, Alexander Vonbank, Barbara Larcher, Arthur Mader, Maximilian Maechler, Beatrix Mutschlechner, Magdalena Benda, Andreas Leiherer, Axel Muendlein, Heinz Drexel, Christoph H Saely
Journal: Circulation (2021)

Introduction: Both type 2 diabetes (T2DM) and chronic kidney disease (CKD) confer a high risk of cardiovascular disease (CVD), and these conditions frequently coincide. Hypothesis: We hypothesize that there are single and joint effects of T2DM and CKD on major cardiovascular events (MACE) in a high-risk population of patients with established coronary artery disease (CAD). Methods: We prospectively investigated 1460 patients with angiographically proven CAD over 10.4±4.8 years, of whom 454 (30.8%) had T2DM and 251 (17.1%) had CKD. Results: MACE occurred more frequently in T2DM patients than in non-diabetic subjects (40.4% vs 28.7%, p&lt;0.001) and in patients with CKD (eGFR &lt; 60ml/min/1.73m 2 ) than in those with an eGRF ≥60ml/min/1.73m 2 (51.6% vs 28.3%, p&lt;0.001). When both, T2DM and CKD were considered, 863 subjects had neither T2DM nor CKD, 346 had T2DM but not CKD, 148 did not have diabetes but had CKD, and 103 had both T2DM and CKD. When compared with the incidence of MACE among patients with neither T2DM nor CKD (25.3%), MACE occurred more frequently in patients with T2DM who did not have CKD (35.8%; p&lt;0.001) as well as in non-diabetic patients with CKD (47.6%; p&lt;0.001) and occurred most frequently in patients with both, T2DM and CKD (57.4%; p&lt;0.001), in whom the incidence of MACE was higher than in those with T2DM but not CKD (p&lt;0.001) or those without T2DM but with CKD (p=0.025); the incidence of MACE was higher in non-diabetic CKD patients than in T2DM patients who did not have CKD (p=0.041). In Cox regression analysis, T2DM (HR=1.46 [1.20-1.78]; p&lt;0.001) and CKD (HR=1.81 [1.45-2.27]; p&lt;0.001) were mutually independent predictors of MACE after multivariate adjustment. Conclusions: We conclude that T2DM and CKD are mutually independent risk factors for MACE in patients with established CAD. CAD patients with both CKD and T2DM are at an extremely high risk for MACE.
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
Authors: Jean-Charles Lambert, Simon Heath, Gael Even, Dominique Campion, Kristel Sleegers, Mikko Hiltunen, Onofre Combarros, Diana Zelenika, Maria J Bullido, Béatrice Tavernier, Luc Letenneur, Karolien Bettens, Claudine Berr, Florence Pasquier, Nathalie Fiévet, Pascale Barberger-Gateau, Sebastiaan Engelborghs, Peter De Deyn, Ignacio Mateo, Ana Franck, Seppo Helisalmi, Elisa Porcellini, Olivier Hanon, Marian M de Pancorbo, Corinne Lendon, Carole Dufouil, Céline Jaillard, Thierry Leveillard, Victoria Alvarez, Paolo Bosco, Michelangelo Mancuso, Francesco Panza, Benedetta Nacmias, Paola Bossù, Paola Piccardi, Giorgio Annoni, Davide Seripa, Daniela Galimberti, Didier Hannequin, Federico Licastro, Hilkka Soininen, Karen Ritchie, Hélène Blanché, Jean-François Dartigues, Christophe Tzourio, Ivo Gut, Christine Van Broeckhoven, Annick Alpérovitch, Mark Lathrop, Philippe Amouyel
Journal: Nature Genetics (2009)
A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with <i>FLT3</i>-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study
Authors: Nicholas J. Short, Courtney D. DiNardo, Naval Daver, Daniel Nguyen, Musa Yilmaz, Tapan M. Kadia, Guillermo Garcia-Manero, Ghayas C. Issa, Xuelin Huang, Wei Qiao, Koji Sasaki, Guillermo Montalban-Bravo, Kelly S. Chien, Gautam Borthakur, Ricardo Delumpa, Anna Milton, Sherry A. Pierce, Elias J. Jabbour, Marina Konopleva, Hagop Kantarjian, Farhad Ravandi
Journal: Blood (2021)
FISH and WGS in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma - WGS Will Affect Future Treatment Decisions
Authors: Marietta Truger, Stephan Hutter, Manja Meggendorfer, K. Martin Kortuem, Niroshan Nadarajah, Wencke Walter, Constance Baer, Leo Rasche, Wolfgang Kern, Torsten Haferlach, Hermann Einsele, Claudia Haferlach
Journal: Blood (2021)
Abstract 2998: Akt-activated endothelium constitute the niche for residual disease and resistance to bevacizumab in ovarian cancer
Authors: Bella Samia Guerrouahen, Jennifer Pasquier, Nadine Abou Kaoud, Marie-Claude Beauchamp, Mahtab Maleki, Pegah Ghiabi, Raphael Lis, Ahmed Saleh, Walter H. Gotlieb, Shahin Rafii, Arash Rafii
Journal: Cancer Research (2014)

Abstract Ovarian cancer is the second leading cause of cancer-related death in women worldwide. Despite optimal cytoreduction and adequate adjuvant therapies, initial tumor response is often followed by relapse suggesting the existence of a tumor niche. Targeted therapies have been evaluated in ovarian cancer to overcome resistant disease. Among them anti-angiogenic therapies inhibit new blood vessel growth, induce endothelial cell apoptosis, and block the incorporation of haematopoietic and endothelial progenitor cells into new blood vessels. Despite in vitro and in vivo successes antivascular therapy with bevacizumab targeting VEGF has limited efficacy in ovarian cancer. The precise molecular mechanisms underlying clinical resistance to anti-VEGF therapies are not yet well understood. Among them tumor and stromal heterogeneity might determine the treatment outcomes. The present study investigates whether abnormalities in the tumor endothelium may contribute to treatment resistance to bevacizumab and promote a residual microscopic disease. Here we showed that ovarian cancer cells (OCC) activate akt phosphorylation in endothelial cells inducing resistance to bevacizumab leading to an autocrine loop based on FGF2 secretion. Altogether our results point out the role of an activated endothelium in the resistance to bevacizumab and in the constitution of a niche for a residual disease. Citation Format: Bella Samia Guerrouahen, Jennifer Pasquier, Nadine Abou Kaoud, Marie-Claude Beauchamp, Mahtab Maleki, Pegah Ghiabi, Raphael Lis, Ahmed Saleh, Walter H. Gotlieb, Shahin Rafii, Arash Rafii. Akt-activated endothelium constitute the niche for residual disease and resistance to bevacizumab in ovarian cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2998. doi:10.1158/1538-7445.AM2014-2998
Approved HIV reverse transcriptase inhibitors in the past decade
Authors: Guangdi Li, Yali Wang, Erik De Clercq
Journal: Acta Pharmaceutica Sinica B (2021)

HIV reverse transcriptase (RT) inhibitors are the important components of highly active antiretroviral therapies (HAARTs) for anti-HIV treatment and pre-exposure prophylaxis in clinical practice. Many RT inhibitors and their combination regimens have been approved in the past ten years, but a review on their drug discovery, pharmacology, and clinical efficacy is lacking. Here, we provide a comprehensive review of RT inhibitors (tenofovir alafenamide, rilpivirine, doravirine, dapivirine, azvudine and elsulfavirine) approved in the past decade, regarding their drug discovery, pharmacology, and clinical efficacy in randomized controlled trials. Novel RT inhibitors such as islatravir, MK-8504, MK-8507, MK8583, IQP-0528, and MIV-150 will be also highlighted. Future development may focus on the new generation of novel antiretroviral inhibitors with higher bioavailability, longer elimination half-life, more favorable side-effect profiles, fewer drug-drug interactions, and higher activities against circulating drug-resistant strains.
Allogeneic and Autologous Hematopoietic Transplants Can be Safely Performed after COVID-19 Infections
Authors: Jeremy L. Ramdial, Rima M. Saliba, Amin M. Alousi, Gabriela Rondon, Julianne Chen, Celina Ledesma, Elizabeth J. Shpall, Roy Chemaly, Richard E. Champlin
Journal: Blood (2021)
Abstract PO-126: Loss of HIF1A decreases resistance to radiation and invasiveness in pancreatic ductal adenocarcinoma
Authors: Kevin J. Tu, Sanjit K. Roy, Binny Bhandary, Amit Sawant, Hem D. Shukla
Journal: Cancer Research (2021)

Abstract Pancreatic ductal adenocarcinoma (PDAC) is the fourth most lethal cancer in the United States with an estimated 60,430 new cases and 48,220 deaths in 2021. PDACs are characterized by extensive desmoplastic stroma and severe hypovascularity, resulting in an intra-tumoral hypoxic microenvironment. In response to hypoxic stress, cancer cells set off many adaptive responses including metabolism regulation, cell survival, and inflammation through the stabilization and activation of the hypoxia-inducible factor (HIF) family of transcription factors. In this study, we used the gene-editing tool CRISPR-cas9 to knock out HIF1A and investigate whether HIF1A affects the radioresistant and invasive characteristics of PDACs in a KPC cell line model. To first observe how HIF1A affects PDAC radioresistance, we performed a clonogenic survival assay with increasing doses of radiation on both wild-type and HIF1A knockout (KO) cells treated and untreated with CoCl2-induced hypoxia conditions (100 uM and 200 uM CoCl2). Our data showed that under hypoxia, KO cells exhibited significant cell death when treated with 6, 8, and 10 Gy of radiation as compared to wild-type KPC cells, emphasizing the role of HIF1A in radiation resistance. In addition, to understand the role of HIF1A in regulating the invasive behavior of PDACs, we performed a cell proliferation assay on wild-type and KO KPC cells. HIF1A KO cells treated with CoCl2 exhibited significantly reduced proliferation compared to wild-type cells also treated with CoCl2 (p&amp;lt;0.01), though no significant difference was observed between untreated HIF1A KO and untreated wild-type cells (p&amp;gt;0.05). Because western blot demonstrated increased HIF1A expression in wild-type cells following CoCl2 treatment, our results provided evidence for the role of HIF1A activation in promoting PDAC invasiveness. Through western blot, we also confirmed the association between HIF1A expression with p53 degradation in PDAC. We used COREMINE, a literature mining tool, to map a direct interaction between HIF1A with KRAS in PDACs (p=0.000016). We propose HIF1A as a switch to activate KRAS and degrade p53 under hypoxic conditions in PDAC proliferation. Thus, modulating the HIF1A switch may be an important mechanism to reduce the tumor-promoting microenvironment and inhibit cancer growth. Citation Format: Kevin J. Tu, Sanjit K. Roy, Binny Bhandary, Amit Sawant, Hem D. Shukla. Loss of HIF1A decreases resistance to radiation and invasiveness in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-126.
Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry
Authors: Fabian Beier, Mareike Tometten, Martin Kirschner, Insa Halfmeyer, Margherita Vieri, Kim Kricheldorf, Angela Maurer, Alexander Roeth, Uwe Platzbecker, Markus P. Radsak, Philippe Schafhausen, Selim Corbacioglu, Britta Hoechsmann, C. Matthias Wilk, Claas Hinze, Jörg Chromik, Alexander Egle, Michael Heuser, Michael Kreuter, Ingo Kurth, Steffen Koschmieder, Jens Panse, Robert Meyer, Susanne Isfort, Tim H Brummendorf
Journal: Blood (2021)
Deregulation of Splicing in Pediatric Acute Myeloid Stem and Progenitor Cells
Authors: Phoebe Mondala, Inge Van Der Werf, Larisa Balaian, Kathleen Steel, Luisa Ladel, Cayla Mason, Raymond Diep, Jacqueline Cloos, Gertjan Kaspers, Markus J van Roosmalen, Ruben Van Boxtel, Warren Chan, Adam Mark, Mary Donohoe, James La Clair, Peggy Wentworth, Kathleen Fisch, Leslie A Crews, Thomas Whisenant, Michael Burkart, Catriona Jamieson
Journal: Blood (2021)
Reverse cuts to children’s centres, peers urge government
Authors: Jacqui Wise
Journal: BMJ (2021)

A nationwide network of family hubs should be put at the core of a national strategy on child vulnerability, a House of Lords committee has recommended.

Over a million vulnerable children are now growing up with reduced life chances because of cuts to early years and youth support since 2010, with the risk of serious harm being felt disproportionately in the most deprived areas, the report from the House of Lords Public Services Committee warns.1 It says poor national coordination leads many children to fall through the gaps.

The government’s 2021 spending review committed to fund a small number of family hubs in half of local authority areas. These offer support for parents and their children between the ages of 0 and 19. But the report says …
Immunohistochemical Expression of Choline Acetyltransferase and Catecholamine-Synthesizing Enzymes in Head-and-Neck and Thoracoabdominal Paragangliomas and Pheochromocytomas
Authors: Noriko Kimura, Kiyoto Shiga, Ken-ichi Kaneko, Yutaka Oki, Chiho Sugisawa, Jun Saito, Seiich Tawara, Hiroshi Akahori, Susumu Sogabe, Takafumi Yamashita, Kazuhiro Takekoshi, Mitsuhide Naruse, Takayuki Katabami
Journal: Endocrine Pathology (2021)
Advancing dental implants: Bioactive and therapeutic modifications of zirconia
Authors: Divya Chopra, Anjana Jayasree, Tianqi Guo, Karan Gulati, Sašo Ivanovski
Journal: Bioactive Materials (2021)

Zirconium-based implants have gained popularity in the dental implant field owing to their corrosion resistance and biocompatibility, attributed to the formation of a native zirconia (ZrO2) film. However, enhanced bioactivity and local therapy from such implants are desirable to enable the earlier establishment and improved long-term maintenance of implant integration, especially in compromised patient conditions. As a result, surface modification of zirconium-based implants have been performed using various physical, chemical and biological techniques at the macro-, micro-, and nano-scales. In this extensive review, we discuss and detail the development of Zr implants covering the spectrum from past and present advancements to future perspectives, arriving at the next generation of highly bioactive and therapeutic nano-engineered Zr-based implants. The review provides in-depth knowledge of the bioactive/therapeutic value of surface modification of Zr implants in dental implant applications focusing on clinical translation.
Autologous Stem Cell Transplantation after Conditioning with Chidamide Plus Carmustine, Etoposide, Cytarabine, and Cyclophosphamide (Chi-BEAC) for Treatment of High-Risk and Relapsed/Refractory Aggressive Lymphoma: Multi-Center, Single-Arm, Open-Label Phase II Clinical Trial
Authors: Wei Xu, Yi Xia, Li Wang, Kaiyang Ding, Huayuan Zhu, Maogui Hu, Hua Yin, Jiazhu Wu, Haorui Shen, Jin-Hua Liang, Jianyong Li
Journal: Blood (2021)
Universally Observed Loss of BCL7A Allows Activation of IRF4 and Its Transcriptional Activity in Multiple Myeloma Cells
Authors: Chandraditya Chakraborty, Srikanth Talluri, Eugenio Morelli, Sanika Derebail, Yao Yao, Yan Xu, Alba Rodríguez García, María Linares, Kenneth C. Anderson, Moritz Binder, Mehmet K. Samur, Mariateresa Fulciniti, Nikhil C. Munshi
Journal: Blood (2021)
Frequency and Survival of T-Cell Lymphomas in Peru: Initial Report of a Peruvian Registry Experience
Authors: Daniel J Enriquez, Jhoisy Casas, Gustavo Sandival, Johan Espino, Evelyn Espinoza-Morales, Elizabeth Cervantes, Melanie Castro-Mollo, Fátima Jiménez-Mozo, Daniela Dueñas, Carlos Barrionuevo, Juan C Haro, Emperatriz Ortega, Katia Roque, Tatiana Vidaurre, Sophia Lozano, Shirley Quintana, Jule Vasquez, Lourdes Lopez, Cindy Alcarraz, Alonso Diaz, Claudio Flores, Cesar Samanez-Figari
Journal: Blood (2021)
Abstract 126: An Interdisciplinary Institutional Algorithm for the Initiation of Mechanical Circulatory Support for Acute Cardiogenic Shock
Authors: John F Lazar, Chelsea Rice, Mathew Schiralli, William Hallinan, Todd Massey
Journal: Circulation (2012)

Introduction. The application of mechanical circulatory support (MCS) for refractory acute cardiogenic shock (aCS) has significantly improved survival in a group of patients that previously faced a...
Longitudinal Transcriptional Analysis of Peripheral Blood Leukocytes in COVID Convalescent Donors
Authors: Mallikarjuna Rao Gedda, Patrick Danaher, Lipei Shao, Martin Ongkeko, Leonard Chen, Mame Thioye Sall, Opal Reddy, Christina Bailey, Amy Wahba, Inna Dzekunova, Valeria De Giorgi, Robert Somerville, Jin Ping, Kamille West, Sandhya R. Panch, David F. Stroncek
Journal: Blood (2021)
Lyme Carditis Presenting as Sinus Node Dysfunction and Accelerated Junctional Rhythm
Authors: Saima Karim, Roy Arjoon, B. Julie He, Lynda Rosenfeld, Paras Bhatt
Journal: Clinical Cardiology and Cardiovascular Interventions (2020)

Lyme disease can have cardiac involvement and can subsequently present with various types of atrio ventricular (AV) block. Sinus node dysfunction (SND) and accelerated junctional rhythm are highlighted in this case as an uncommon presentation for Lyme Carditis. This case highlights the importance of having a high index of suspicion for cardiac involvement with Lyme disease when atypical arrhythmias are present.
Outcomes of Direct Oral Anticoagulants with Aspirin Versus Warfarin with Aspirin for Atrial Fibrillation and/or Venous Thromboembolic Disease
Authors: Jordan K Schaefer, Josh Errickson, Xiaowen Kong, Tina Alexandris-Souphis, Mona A Ali, Subhash Edupuganti, Brian Haymart, Scott Kaatz, Eva Kline-Rogers, Jay H Kozlowski, Gregory D Krol, Vinay Shah, Suman L Sood, James B Froehlich, Geoffrey D Barnes
Journal: Blood (2021)
Abstract 9552: Understanding the Costs Associated With Cardiac Ablations
Authors: Megan K Kawasaki, David J Cleary, Daniel D Correa de Sa, Susan R Calame, Christopher M Dillon, Mitchell H Tsai
Journal: Circulation (2019)

Introduction: As non-operating room anesthesia (NORA) services become increasingly common, an accurate understanding of their costs is important for assessing efficiency and identifying areas of pr...
Increasing Prevalence of Critical Limb Ischemia Hospitalizations With Distinct Mental Health Burden Among Younger Adults
Authors: Kristie M. Harris, Carlos Mena-Hurtado, Ahmad Arham, Matthew M. Burg, Kenneth E. Freedland, Rajita Sinha, Olamide Alabi, Kim G. Smolderen
Journal: Journal of the American College of Cardiology (2021)
Low Rates of Venoocclusive Disease and Non-Relapse Mortality in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation Following Inotuzumab Ozogamicin Reinduction for Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Authors: Jonathan D. Paolino, Jiemin Yang, Andrew E. Place, Christine N. Duncan, Steven P. Margossian, Leslie E. Lehmann, John T. Horan, Malika Kapadia, Jennifer S. Whangbo, Francesca Alvarez Calderon, Melissa A. Burns, Leslie S. Kean, Lewis B. Silverman, Donna S. Neuberg, Susanne H.C. Baumeister
Journal: Blood (2021)
Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Paul Harker-Murray, Brent L. Wood, Meenakshi Devidas, Zhiguo Chen, Tal Schechter-Finkelstein, Robert J. Hayashi, Keith J August, Kimberly P. Dunsmore, Michelle L. Hermiston, Terzah M. Horton, Yoav H. Messinger, Sarah L Vargas, Eric S Schafer, Maria Luisa Sulis, Stuart S. Winter, Charlotte Wood, Catherine M Bollard, Mignon L. Loh, Stephen P Hunger, Elizabeth A. Raetz, David T. Teachey
Journal: Blood (2021)
Vitamin B5 and Succinyl-CoA Improve Ineffective Erythropoiesis in SF3B1 Mutated Myelodysplasia
Authors: Syed Mian, Celine Philippe, Eleni Maniati, Tiffany Bergot, Marion Piganeau, Doriana Di Bella, Valle Morales, Andrew Finch, Katiuscia Bianchi, Jun Wang, Paolo Gallipoli, Uwe Platzbecker, Daniel H Wiseman, Dominique Bonnet, Delphine Bernard, John Gribben, Kevin Rouault-Pierre
Journal: Blood (2021)
The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models
Authors: Reona Sakemura, Paulina Horvei, Claudia Manriquez-Roman, Ekene J. Ogbodo, Erin E. Tapper, Elizabeth L. Siegler, Carli M. Stewart, Kendall J. Schick, Ismail Can, Mohamad M. Adada, Evandro D. Bezerra, Lionel A. Kankeu Fonkoua, Mehrdad Hefazi, Michael W. Ruff, Christian Augsberger, Juergen Schanzer, Maria Patra-Kneuer, Christina Heitmüller, Stefan Steidl, Jan Endell, Wei Ding, Sameer A. Parikh, Susan L. Slager, Neil E. Kay, Grzegorz S. Nowakowski, Michelle J. Cox, Saad S. Kenderian
Journal: Blood (2021)
Integrated Analysis of B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Relapsed and Refractory Multiple Myeloma Subjects By High-Risk Factors
Authors: Chengcheng Fu, Songfu Jiang, Jie Jin, Wenming Chen, Siguo Hao, Zhen Cai, Zonghai LI, Lingzhi Yan, Kang Yu, Min Yang, Huijuan Wang, Wenhao Zhang, Xiaoyan Han, Wei Wang, Hongxia Zhao
Journal: Blood (2021)
NHS litigation system fails to deliver justice or learn from mistakes, MPs hear
Authors: Clare Dyer
Journal: BMJ (2021)

The NHS’s litigation system is facing ballooning costs while failing to deliver justice or to learn lessons when treatment goes wrong, parents and experts have told a parliamentary investigation into reform of the system.

Parents of three children who died as a result of botched care told the House of Commons health and social care committee of having struggled for years to find out what had gone wrong.

Sue Beeby’s son Jasper was born with severe brain damage after a series of mistakes in her maternity care. He died aged 2 from pneumonia, but it took a further …
Long-Term Treatment with Pacritinib on a Compassionate Use Basis in Patients with Advanced Myelofibrosis
Authors: Claire N. Harrison, Abdulraheem Yacoub, Bart L. Scott, Adam J. Mead, Aaron T. Gerds, Jean-Jacques Kiladjian, Ruben A. Mesa, Miklos Egyed, Christof Scheid, Valentín Garcia Gutierrez, Sarah A Buckley, Kris Kanellopoulos, John Mascarenhas
Journal: Blood (2021)
Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-
Authors: Martin Bornhaeuser, Christoph Schliemann, Johannes Schetelig, Christoph Rollig, Michael Kramer, Bertram Glass, Uwe Platzbecker, Andreas Burchert, Mathias Haenel, Lutz Peter Mueller, Stefan Klein, Gesine Bug, Dietrich W. Beelen, Wolf Roesler, Kerstin Schaefer-Eckart, Christoph Schmid, Edgar Jost, Georg Lenz, Johanna Tischer, Karsten Spiekermann, Markus Pfirrmann, Hubert Serve, Friedrich Stoelzel, Nael Alakel, Gerhard Ehninger, Wolfgang E. Berdel, Matthias Stelljes
Journal: Blood (2021)
Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial
Authors: Carlo Gambacorti-Passerini, Tim H Brümmendorf, Elisabetta Abruzzese, Kevin R. Kelly, Vivian G. Oehler, Valentín Garcia-Gutiérrez, Henrik Hjorth-Hansen, Thomas Ernst, Eric Leip, Simon Purcell, Gerald Luscan, Andrea Viqueira, Frank Giles, Andreas Hochhaus
Journal: Blood (2021)